You just read:

DelMar Pharmaceuticals Updates Ongoing Phase I/II Refractory GBM Clinical Trial with VAL-083 at American Association Cancer Research (AACR) Annual Meeting

News provided by

DelMar Pharmaceuticals, Inc.

19 Apr, 2016, 09:10 ET